No annual revenue total was found in Indaptus Therapeutics, Inc.'s SEC filings.
Indaptus Therapeutics, Inc. (INDP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-15.42M
+9.1% vs year-ago TTM
Operating cash flow (TTM)
$-14.70M
+1.9% vs year-ago TTM
Free cash flow
$-11.29M
EPS (TTM)
$-0.48
+98.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.24M
-84.5% vs prior year
Net cash
$5.70M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1857044
- Former names
- Intec Parent Inc. (until Aug 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M |
| Diluted EPS | -$21.58 | -$44.96 | -$1.83 | — | — |
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Free cash flow | — | — | — | — | -$11.3M |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M |
| Stockholders' equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M |
| Cash and investments | $8.5M | $5.8M | $13.4M | $26.4M | $39.1M |
| Total debt | — | $84,164 | $175,053 | $80,494 | $169,327 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 10, 2026 | Sep 8, 2026 |
| 8-K/A |
Amended current report
Material agreement
|
Sep 8, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 1, 2026 | Aug 28, 2026 |
All 343 Indaptus Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.